CEO Tim Van Hauwermeiren emphasized 2024 as a "phenomenal year," highlighted by expanding the reach of VYVGART to over 10,000 patients globally across three approved indications. He noted the ...
Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that ...
ADAPT OCULUS is the first study to evaluate a targeted treatment for ocular MG, demonstrating that VYVGART significantly improves disease ...
(RTTNews) - Takeda Pharmaceutical Co. Ltd. (TAK) announced Tuesday favorable long-term data from the Phase 3 ADVANCE-CIDP 3 clinical trial of HYQVIA in Patients with Chronic Inflammatory Demyelinating ...
NVG-2089 is a recombinant Fc fusion protein designed to replicate key immunomodulatory functions of IVIg with greater consistency, scalability, and patient convenience Phase 1 data show NVG-2089 was ...
Folia Health today announced a collaboration with argenx to launch a first-of-its-kind, at-home observational real-world evidence initiative supporting individuals living with chronic inflammatory ...
Takeda is making its first foray into rare disease marketing on connected TV (CTV). The Japanese biotech recently launched a video campaign for its chronic inflammatory demyelinating polyneuropathy ...
Please provide your email address to receive an email when new articles are posted on . Reasons for misdiagnosis or delayed diagnosis for CIDP are complex and include multiple factors. The FDA ...
PHOENIX -- A subcutaneous infusion of efgartigimod cut the risk of relapse in patients with a rare but serious immune-mediated neuropathy, according to the phase II ADHERE trial. Patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results